Accordingly, the neuroprotection and motor control afforded by A2AR antagonists in PD occur through different mechanisms [30], and synaptic A2AR display a gain of function in the PD prodrome controlling aberrant corticostriatal plasticity and the onset of motor symptoms in a 6-hydroxydopamine model of PD [12]. This evidence concerns the gene ADORA2A and Parkinson disease.